XML 55 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Industry Segment and Geographic Area Information
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Industry Segment Information Industry Segment and Geographic Area Information
The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income as adjusted for certain items. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1.
The principal products and services of the Company’s two reportable segments are:
•Life Sciences. Provides products and services targeted towards the life sciences customers.
•Diagnostics. Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, emerging market diagnostics and applied genomics.
The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
The primary financial measure by which the Company evaluates the performance of its segments is adjusted operating income, which consists of operating income plus amortization of intangible assets, adjustments to operations arising from purchase accounting (primarily adjustments to the fair value of acquired inventory that are subsequently recognized), acquisition and divestiture-related costs, and other costs that are not expected to recur or are of a non-cash nature, including primarily restructuring actions.

Revenue and operating income from continuing operations by reportable segment are shown in the table below for the fiscal years ended: 
December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
Revenues
Life Sciences$1,292,340 $1,292,909 $897,718 
Diagnostics1,459,058 2,019,727 2,932,738 
Revenue purchase accounting adjustments(827)(814)(2,648)
Total revenues$2,750,571 $3,311,822 $3,827,808 
Segment Operating Income
Life Sciences$489,349 $503,243 $281,602 
Diagnostics320,928 781,985 1,432,769 
Corporate(40,417)(73,431)(77,364)
Subtotal reportable segments769,860 1,211,797 1,637,007 
Amortization of intangible assets(365,113)(370,638)(256,569)
Purchase accounting adjustments(5,956)(45,681)(40,993)
Acquisition and divestiture-related costs(69,159)(39,826)(62,760)
Asset impairment— — (3,767)
Significant litigation matters and settlements(12)627 (103)
Significant environmental matters(2,457)— — 
Restructuring and other, net(26,601)(13,580)(14,358)
Operating income from continuing operations300,562 742,699 1,258,457 
Interest and other expense, net117,586 90,862 54,875 
Income from continuing operations before income taxes$182,976 $651,837 $1,203,582 
Additional information relating to the Company’s reportable segments is as follows for the three fiscal years ended December 31, 2023:
 Depreciation and Amortization ExpenseCapital Expenditures
 December 31,
2023		January 1,
2023		January 2,
2022		December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)(In thousands)
Life Sciences$276,118 $263,698 $94,700 $35,335 $41,532 $27,818 
Diagnostics153,099 161,394 214,178 39,894 40,671 57,206 
Corporate2,552 1,908 2,565 6,139 3,429 996 
Continuing operations$431,769 $427,000 $311,443 $81,368 $85,632 $86,020 
 Total Assets
 December 31,
2023		January 1,
2023
 (In thousands)
Life Sciences$8,401,851 $8,330,045 
Diagnostics4,136,305 3,991,659 
Corporate1,026,509 114,447 
Current and long-term assets of discontinued operations— 1,693,704 
Total assets$13,564,665 $14,129,855 
The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 31, 2023 and net long-lived assets based on physical location as of December 31, 2023 and January 1, 2023:
 Revenue
 December 31,
2023		January 1,
2023		January 2,
2022
 (In thousands)
U.S.$1,117,654 $1,546,520 $1,682,294 
International:
China454,426 476,366 449,588 
United Kingdom125,419 136,017 357,911 
Other international1,053,072 1,152,919 1,338,015 
Total international1,632,917 1,765,302 2,145,514 
Total revenue$2,750,571 $3,311,822 $3,827,808 
 
 
Net Long-Lived Assets(1)
 December 31,
2023		January 1,
2023
 (In thousands)
U.S.$317,226 $311,661 
International:
Germany158,228 147,766 
China59,602 68,072 
Other international223,820 216,235 
Total international441,650 432,073 
Total net long-lived assets$758,876 $743,734 
(1) Long-lived assets consist of property and equipment, net, operating lease right-of-use assets, rental equipment, software and other long-term assets.